| Owner | Title | From | %Ownership |
|---|---|---|---|
| Legorreta, Pablo, Gerardo | Chief Executive Officer and Managing Member | 08/2003 | > 75% |
| Lloyd, George, Wingate | Executive Vice President and Chief Legal Officer | 07/2011 | < 5% |
| Reddoch, James, Folmar | Executive Vice President | 07/2008 | < 5% |
| Erb, Douglas, Peter | Chief Administrative Officer and Chief Technology Officer | 12/2014 | < 5% |
| Coyne, Terrance, Patrick | Chief Financial Officer | 03/2019 | < 5% |
| Rubin, Carolyn, Judith | Chief Compliance Officer | 03/2022 | < 5% |
| Mcgivern, Arthur, Richard | Executive Vice President and General Counsel | 10/2022 | < 5% |
| Fund structure | AUM | Fund type |
|---|---|---|
| RP Management, LLC | $17.02 bn | |
| Royalty Pharma Select | $40.95 mm | Private Equity Fund |
| Royalty Pharma Cayman Holdings 2008, LP | ||
| Royalty Pharma Cayman Holdings, LP | ||
| Royalty Pharma Us Partners LP | ||
| Royalty Pharma Us Partners 2008, LP | ||
| Royalty Pharma Cayman Partners, LP | ||
| Royalty Pharma Cayman Partners 2008, LP | ||
| RPS Biopharma Investments, LP | ||
| RPS Biopharma Holdings, LP | ||
| Rpi Intermediate Finance Partnership, LP | $1.68 bn | Hedge Fund |
| Rpi International Partners II, LP | ||
| Rpi International Partners, LP | ||
| Rpi Us Partners, LP | ||
| Rpi Us Partners II, LP | ||
| Rpi International Holdings, LP | ||
| Rpi International Partners 2019, LP | $22.18 mm | Private Equity Fund |
| Rpi International Holdings 2019, LP | ||
| Rpi Us Partners 2019, LP | $1.45 bn | Private Equity Fund |
